Equities analysts forecast that Heron Therapeutics Inc (NASDAQ:HRTX) will post sales of $24.50 million for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Heron Therapeutics’ earnings. The lowest sales estimate is $22.50 million and the highest is $28.00 million. Heron Therapeutics posted sales of $10.05 million during the same quarter last year, which suggests a positive year-over-year growth rate of 143.8%. The company is expected to announce its next quarterly earnings report on Tuesday, February 26th.

According to Zacks, analysts expect that Heron Therapeutics will report full year sales of $73.26 million for the current fiscal year, with estimates ranging from $71.13 million to $77.00 million. For the next fiscal year, analysts expect that the firm will post sales of $177.08 million, with estimates ranging from $147.00 million to $224.80 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.49) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.44) by ($0.05). Heron Therapeutics had a negative return on equity of 72.23% and a negative net margin of 326.79%. The company had revenue of $19.79 million during the quarter, compared to the consensus estimate of $19.84 million. During the same period last year, the firm posted ($0.77) earnings per share. The company’s revenue was up 130.9% compared to the same quarter last year.

Several research analysts have recently weighed in on HRTX shares. ValuEngine cut Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, September 4th. Cantor Fitzgerald set a $50.00 price target on Heron Therapeutics and gave the stock a “buy” rating in a research note on Thursday, September 27th. Stifel Nicolaus started coverage on Heron Therapeutics in a research note on Thursday, September 13th. They issued a “buy” rating and a $55.00 price target for the company. BidaskClub cut Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, September 22nd. Finally, Zacks Investment Research upgraded Heron Therapeutics from a “sell” rating to a “buy” rating and set a $34.00 price target for the company in a research note on Thursday, October 11th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eleven have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $52.09.

Heron Therapeutics stock opened at $27.85 on Friday. Heron Therapeutics has a 12 month low of $15.00 and a 12 month high of $42.90. The firm has a market capitalization of $2.15 billion, a price-to-earnings ratio of 7.63 and a beta of 1.45.

In related news, VP Kimberly Manhard sold 6,000 shares of the company’s stock in a transaction on Monday, October 1st. The stock was sold at an average price of $32.07, for a total transaction of $192,420.00. Following the completion of the sale, the vice president now owns 6,000 shares in the company, valued at $192,420. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Kevin C. Tang sold 2,695,000 shares of the company’s stock in a transaction on Wednesday, September 12th. The shares were sold at an average price of $35.75, for a total value of $96,346,250.00. The disclosure for this sale can be found here. Insiders sold 2,701,494 shares of company stock valued at $96,553,796 in the last 90 days. Company insiders own 16.20% of the company’s stock.

A number of institutional investors have recently bought and sold shares of HRTX. Amalgamated Bank purchased a new stake in Heron Therapeutics during the second quarter valued at $379,000. NewSquare Capital LLC purchased a new stake in Heron Therapeutics during the second quarter valued at $211,000. Pier 88 Investment Partners LLC purchased a new stake in Heron Therapeutics during the second quarter valued at $451,000. Aperio Group LLC increased its position in Heron Therapeutics by 14.4% during the second quarter. Aperio Group LLC now owns 11,261 shares of the biotechnology company’s stock valued at $437,000 after acquiring an additional 1,416 shares during the last quarter. Finally, Wells Fargo & Company MN increased its position in Heron Therapeutics by 339.1% during the second quarter. Wells Fargo & Company MN now owns 265,847 shares of the biotechnology company’s stock valued at $10,329,000 after acquiring an additional 205,302 shares during the last quarter.

About Heron Therapeutics

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

See Also: Average Daily Trade Volume Explained

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.